Mirum's Livmarli (maralixibat) Receives US FDA's Approval as the First Approved Therapy for Cholestatic Pruritus in Patients with Alagille Syndrome
- The approval is based on the ICONIC study as well as 5yrs. of data from supportive studies that evaluate Livmarli in 86 patients with ALGS
- The results from the ICONIC study demonstrated a significant reduction in pruritus that was maintained through 4yrs.
- Livmarli is the first FDA-approved therapy for patients aged ≥1yrs. & the company has received a rare pediatric disease priority review voucher. The therapy will now be accessible to patients with a prescription through MAP that provides insurance coverage- and access support along with financial support options for patients with Livmarl
| Ref: Mirum | Image: Businesswire
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at email@example.com